Cancer News: Leukemia and lymphoma
Heavily treated patients with relapsed or refractory mantle cell lymphoma (MCL) showed positive and durable results when treated with Imbruvica, a new report reveals.
Experimental treatment offered critical time for patients of a rare, deadly leukemia, offering also a potential treatment option for other cancers, a small study shows.
Patients with relapsed chronic lymphocytic leukemia (CLL) responded well to treatment with a chemotherapy-free combination therapy, a new small clinical trials showed.
Patients with gastrointestinal stromal tumors may develop additional malignancies before and after their diagnosis, according to the first population-based study.
Results of a new clinical trial showed that most early-stage Hodgkin's lymphoma patients remained relapse-free 3 years after chemotherapy, regardless of radiation.
Lower vitamin D levels prior to treatment to follicular lymphoma patients may cause earlier disease relapse, a new study reveals.
The new drug brentuximab vedotin increased progression free survival in adults with hard-to-treat Hodgkin lymphoma treated immediately after stem cell transplant.
Blinatumomab was approved by the U.S. Food and Drug Administration for the treatment of some forms of acute lymphoblastic leukemia.
Scientists report that 87% of Hodgkin lymphoma patients who participated in an early-phase immunotherapy clinical trial experienced cancer remission.
A new drug against adult relapsed or refractory mantle cell lymphoma (MCL), and adult chronic lymphocytic leukemia (CLL) has been approved in Europe.
Personalized treatment achieved remission in 90% of children & adults with acute lymphoblastic leukemia who relapsed or failed to respond to standard treatment.
Stage 1 & 2 Hodgkin's Disease patients who receive consolidated radiation therapy have a higher 10-year survival rate of 84% vs 76% for patients who did not.
Researchers quantified the risk for non-Hodgkin Lymphoma from medical history, lifestyle factors, family history of blood or lymph-related cancers & occupation.
U.S. regulators on Friday approved Roche Holding AG's new drug for patients with chronic lymphocytic leukemia (CLL) who have not previously been treated for one of the most common forms of blood cancer.
The FDA approved ibrutinib (Imbruvica) on Wednesday for treatment of patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.
Adelaide researchers have found that a specific gene plays an important role in suppressing lymphoma, a type of blood cell cancer.
In two separate studies, researchers successfully identified and validated a gene known as Sox4 as a potential therapeutic target and a class of anti-cancer drugs, histone deacetylase (HDAC) inhibitors, as potential candidates in the treatment of certain AML.
A closely watched leukemia drug maintained its effectiveness in keeping the disease at bay for most patients, according to long-term follow-up data from a midstage study being presented at a major medical meeting.
An experimental drug for leukemia controlled or eliminated signs of the disease in more than 80% of patients who had failed to benefit from previous treatments. This is an unprecedented finding that could spur use of the medicine for other cancers.
A next generation genetic therapy appeared to restore the immune system of patients with "bubble boy disease," but without leading to leukemia as a side effect, researchers reported.
Poor-risk chronic lymphocytic leukemia (CLL) patients had much longer survival when treated with an experimental drug plus rituximab.
Relapsed or refractory Hodgkin lymphoma patients following autologous stem cell transplant achieved a longer median overall survival with brentuximab vedotin.
Research on neoplasms like Chronic Myeloid Leukemia (CML) finds another genetic element towards diagnosis.
A new study helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia.
Men's odds of conception after treatment for Hodgkin's lymphoma doubled with pre-treatment cryopreservation of semen, Dutch investigators reported.
The mechanism of premature cell aging can help treat cancer. Treatments for acute promyelocytic leukemia cause similar effects which can be used for other cancers as well, according to the latest research on this rare type of blood cancer.
The US FDA approved the targeted drug ibrutinib (Imbruvica) as 2nd-line treatment for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
An experimental drug known as dinaciclib could improve the effectiveness of certain multiple myeloma and myeloid leukemia therapies, according to a study.
A pill may be an option for leukemia and lymphoma patients, as researchers are investigating potential alternatives to chemotherapy and immunotherapy.
European regulators have approved a subcutaneous form of MabThera for non-Hodgkin Lymphoma. This reduces patient treatment time from 2.5 hours to 5 minutes.